Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Andernach – page 3

605 clinical trials in Andernach, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Andernach at a glance
605
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

605 trials in Andernach

Open in trial search

Cardiac failure

Recruiting

Study on BI 690517 and Empagliflozin for Patients with Heart Failure and Preserved Ejection Fraction

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:BI 690517
  • Sponsor:Boehringer Ingelheim International GmbH

Study on the Safety of BHV-7000 for Adults with Hard-to-Treat Focal Onset Epilepsy

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:BHV-7000
  • Sponsor:Biohaven Therapeutics Ltd.

Study on Selatogrel for Preventing Heart Attack in Patients with Recent Heart Attack History

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Selatogrel
  • Sponsor:Viatris Innovation GmbH

Breast cancer+1

Recruiting

Study on the Effectiveness of GP2 and Sargramostim for HER2 Positive Breast Cancer Patients with Residual Disease or High-Risk After Standard Therapy

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Molgramostim
  • Sponsor:Greenwich LifeSciences Inc.

Study on the Safety and Effectiveness of Dazucorilant for Patients with Amyotrophic Lateral Sclerosis (ALS)

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Dazucorilant
  • Sponsor:Corcept Therapeutics Inc.

Efficacy and safety of gadopiclenol versus gadoteric acid‑enhanced MRA in adult patients with suspected vascular disease

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Gadopiclenol
  • Sponsor:Bracco Imaging S.p.A.

Study of Rilvegostomig or Pembrolizumab for First-line Treatment in Patients with PD-L1-high Metastatic Non-small Cell Lung Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Infliximab
  • Sponsor:AstraZeneca AB

Study on Bortezomib and Drug Combination for Children with High-Risk Relapsed Acute Lymphoblastic Leukemia (ALL)

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Bortezomib
  • Sponsor:Charite Universitaetsmedizin Berlin KöR

Study of Camizestrant for Patients with ER+/HER2- Early Breast Cancer After 2 Years of Standard Endocrine Therapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:AstraZeneca AB

Efficacy and Safety of Three Different Doses of Pirtobrutinib in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Previously Received BTK Inhibitor Treatment

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Pirtobrutinib
  • Sponsor:Eli Lilly & Co.

Efficacy and Safety of BI 1015550 in Adults with Fibrosing Interstitial Lung Disease at Risk of Disease Progression: A Randomized, Placebo‑Controlled Trial

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Nerandomilast
  • Sponsor:Boehringer Ingelheim Espana S.A.

Comparing Daraxonrasib Alone or Combined with Gemcitabine and Paclitaxel Albumin‑Bound vs Standard Chemotherapy in Patients with Metastatic Pancreatic Adenocarcinoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Daraxonrasib
  • Sponsor:Revolution Medicines Inc.

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Andernach

What the registry says about research in the country

01 Analytical, Diagnostic and Therapeutic Techniques and Equipment

Researchers in Andernach are evaluating innovative cell‑based therapies and delivery platforms aimed at repairing knee cartilage damage.

  • Safety profile of UC‑MSC applied on a collagen scaffold
  • Use of Chondro‑Gide® as a supportive matrix
  • Development of minimally invasive implantation methods
  • Implementation of quantitative outcome tools such as KOOS

Both studies are actively recruiting at the sole research site in Andernach, aiming to generate data that could inform future diagnostic and therapeutic standards.

02 Musculoskeletal Diseases

Clinical efforts focus on restoring damaged knee joint cartilage, a prevalent musculoskeletal concern.

  • Evaluation of minced cartilage implantation (AMCI) versus matrix‑associated autologous chondrocyte implantation
  • Management of full‑thickness knee cartilage lesions
  • Assessment of functional recovery through KOOS scores
  • Exploration of long‑term joint health outcomes

The trials seek to improve treatment options for patients with large cartilage injuries and reflect Andernach’s commitment to advancing musculoskeletal research.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.